Your browser doesn't support javascript.
loading
Development of an Electronic Decision Aid Tool to Facilitate Mainstream Genetic Testing in Ovarian Cancer Patients.
Shannon, Kristen M; Patel, Devanshi; Jonas, Jessica M; Blouch, Erica L; Hicks, Stephanie R; Wooters, Mackenzie; Seidel, Meredith; Grant, Carly F; Emmet, Margaret M; Chung, Daniel C; Sepucha, Karen.
Afiliação
  • Shannon KM; Massachusetts General Hospital Center for Cancer Risk Assessment, Boston, MA, USA.
  • Patel D; Massachusetts General Hospital Center for Cancer Risk Assessment, Boston, MA, USA.
  • Jonas JM; Massachusetts General Hospital Center for Cancer Risk Assessment, Boston, MA, USA.
  • Blouch EL; Massachusetts General Hospital Center for Cancer Risk Assessment, Boston, MA, USA.
  • Hicks SR; Massachusetts General Hospital Center for Cancer Risk Assessment, Boston, MA, USA.
  • Wooters M; Massachusetts General Hospital Center for Cancer Risk Assessment, Boston, MA, USA.
  • Seidel M; Massachusetts General Hospital Center for Cancer Risk Assessment, Boston, MA, USA.
  • Grant CF; Massachusetts General Hospital Center for Cancer Risk Assessment, Boston, MA, USA.
  • Emmet MM; Massachusetts General Hospital Center for Cancer Risk Assessment, Boston, MA, USA.
  • Chung DC; Massachusetts General Hospital Center for Cancer Risk Assessment, Boston, MA, USA.
  • Sepucha K; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
Oncologist ; 29(5): e665-e671, 2024 May 03.
Article em En | MEDLINE | ID: mdl-38297990
ABSTRACT

BACKGROUND:

Multigene panel testing is an important component of cancer treatment plans and risk assessment, but there are many different panel options and choosing the most appropriate panel can be challenging for health care providers and patients. Electronic tools have been proposed to help patients make informed decisions about which gene panel to choose by considering their preferences and priorities. MATERIALS AND

METHODS:

An electronic decision aid (DA) tool was developed in line with the International Patient Decision Aids Standards collaboration. The multidisciplinary project team collaborated with an external health care communications agency and the MGH Cancer Center Patient and Family Advisory Council (PFAC) to develop the DA. Surveys of genetic counselors and patients were used to scope the content, and alpha testing was used to refine the design and content.

RESULTS:

Surveys of genetic counselors (n = 12) and patients (n = 228) identified common themes in discussing panel size and strategies for helping patients decide between panels and in identifying confusing terms for patients and distribution of patients' choices. The DA, organized into 2 major sections, provides educational text, graphics, and videos to guide patients through the decision-making process. Alpha testing feedback from the PFAC (n = 4), genetic counselors (n = 3) and a group of lay people (n = 8) identified areas to improve navigation, simplify wording, and improve layout.

CONCLUSION:

The DA developed in this study has the potential to facilitate informed decision-making by patients regarding cancer genetic testing. The distinctive feature of this DA is that it addresses the specific question of which multigene panel may be most suitable for the patient. Its acceptability and effectiveness will be evaluated in future studies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Testes Genéticos / Técnicas de Apoio para a Decisão / Aconselhamento Genético Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Testes Genéticos / Técnicas de Apoio para a Decisão / Aconselhamento Genético Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos